Israel Biotech Fund

Israel Biotech Fund is dedicated to advancing Israeli biotechnology by identifying and nurturing therapeutic assets from companies based in Israel. Strategically headquartered in Rehovot, the heart of Israel's biotechnology ecosystem, the fund employs a specialized investment approach targeting biotech ventures with drug candidates at or approaching clinical trial stages. Their investor base comprises a diverse coalition of stakeholders including major pharmaceutical corporations, institutional investors, family offices, and high-net-worth individuals who share their vision for Israeli biotech innovation.

What distinguishes this fund is their exceptional network of 25 Venture Advisors - industry luminaries who provide hands-on guidance to portfolio companies. This advisory team includes prominent figures such as Sol Barer, former Chairman and CEO of Celgene; Jeff Kindler, who previously served as Chairman and CEO of Pfizer; Robert Spiegel, former Chief Medical Officer at Schering-Plough; and Murray A. Goldberg, who was CFO at Regeneron. This concentration of pharmaceutical industry expertise creates a powerful knowledge base that portfolio companies can leverage for strategic development.

The fund was co-founded by an experienced leadership team including General Partners David Sidransky, M.D., Yuval Cabilly, Ph.D., and Ido Zairi, who bring complementary skills in scientific research, business development, and investment strategy. Their combined expertise enables the fund to go beyond traditional investment activities by providing comprehensive support throughout the drug development process. This includes strategic guidance, regulatory navigation assistance, clinical trial design expertise, and access to global pharmaceutical networks - resources that are particularly valuable for emerging biotech companies facing the complex challenges of drug development.

Israel Biotech Fund's mission extends beyond financial returns to strengthening Israel's entire biotechnology sector. By providing crucial resources for sustainable growth, the fund helps portfolio companies enhance their valuation while simultaneously developing Israel's biotech infrastructure. This dual approach creates a virtuous cycle: successful companies attract additional investment to the region, expanding opportunities for the fund and its investors. Their commitment to realizing the potential of Israel's biotechnology industry positions them as both a catalyst for individual company success and a strategic architect of the country's emerging position as a global biotech innovation hub.